Robert G. Wilcox

Nottingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

β-Blockers, heart disease and COPD: current controversies and uncertainties.

β-Blockers, heart disease and COPD: current controversies and uncertainties.

Journal: Thorax

Published: May 10, 2016

Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.

Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.

Journal: European heart journal

Published: November 02, 2015

Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction?

Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction?

Journal: Journal of the American Heart Association

Published: August 26, 2015

ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up.

ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up.

Journal: Circulation

Published: August 28, 2014

Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged.

Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged.

Journal: Heart (British Cardiac Society)

Published: August 21, 2014

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.

Journal: Current medical research and opinion

Published: July 16, 2014

The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

Journal: Trials

Published: July 06, 2014

Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study).

Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study).

Journal: The American journal of cardiology

Published: April 28, 2014

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.

Journal: The New England journal of medicine

Published: March 12, 2013

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Journal: Lancet (London, England)

Published: August 31, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026